Conduct of Research and Development. As of the Effective Date, ADT has conducted all Research and Development of Compounds and Products in accordance with all Applicable Law.
Conduct of Research and Development. RiboGene and HPI shall work diligently and use reasonable good faith efforts to identify and develop Joint Compounds and to commercialize Products pursuant to the following restrictions:
6.1.1 The parties shall be entitled to exercise prudent and reasonable business judgement in meeting the obligations of this Section 6.1.
Conduct of Research and Development. As of the Effective Date, Eagle has conducted Development of Licensed Compounds and Licensed Products in accordance with all applicable Law.
Conduct of Research and Development. The parties will conduct their respective Research and Development activities under the Annual Research Plan in good 5. scientific manner and in compliance with all applicable governmental, regulatory and legal requirements. Neurocrine and Rigel will each use their good faith scientific and business judgment to allocate sufficient time, effort, equipment and facilities to. the Collaboration to achieve the objectives of the Collaboration consistent with the terms of this Agreement and the recommendations of the Steering Committee, as provided in Section 3 below.
Conduct of Research and Development. PROGRAM During the Research Term, CPG shall:
a) undertake RESEARCH AND DEVELOPMENT PROGRAM with SB as set forth in Appendix C as further completed by the STEERING COMMITTEE, and such other activities which, from time to time, the STEERING COMMITTEE decides as being necessary for the success of the RESEARCH AND DEVELOPMENT PROGRAM, provided that such decision is consistent with the RESEARCH AND DEVELOPMENT PROGRAM and the terms and conditions of this Agreement. It is understood that (i) SB shall be under no, obligation to participate in the RESEARCH AND DEVELOPMENT PROGRAM other than by providing funding and scientific input as set forth herein and by participating in discussions during the EVALUATION PERIOD (as such period may be extended) regarding the PATENTS and potential claims thereafter and (ii) that CPG shall have no obligation to provide resources for the performance of the RESEARCH AND DEVELOPMENT PROGRAM other than as set forth in Appendix C or as otherwise mutually agreed.
Conduct of Research and Development. During the 12 month period commencing on the January 1, 1998, each of Elan and Endorex shall undertake to perform research and development related to the commercialisation of Products in an amount of approximately $1.5 million each, as stated in the Business Plan, in furtherance of the development and cultivation of the Program Technology. Subsequent to December 31, 1998, Elan and Endorex shall fund research and development work in accordance with their respective ownership interest in the Company. The cost of such development work shall be each Party's respective Cost plus 40%.
Conduct of Research and Development. As of the Execution Date, Licensor and its Affiliates have conducted all Development of Licensed Antibodies and Licensed Products in accordance with all applicable law in all material respects.
Conduct of Research and Development. As of the Effective Date, Hansoh and its Affiliates have conducted all research and development of Licensed Compounds and Licensed Products in accordance with all applicable Law.
Conduct of Research and Development. [***], Exicure has conducted all Research and Development of SNAs in accordance with all Applicable Law.
Conduct of Research and Development. HFB and its Affiliates have conducted all Development of Licensed Compound and Option Compound in accordance with all Applicable Law.
